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Abstract
MicroRNAs are a large class of post-transcriptional regulators that bind to the 39 untranslated region of messenger RNAs.
They play a critical role in many cellular processes and have been linked to the control of signal transduction pathways.
Recent studies indicate that microRNAs can function as tumor suppressors or even as oncogenes when aberrantly
expressed. For more general insights of disease-associated microRNAs, we analyzed their impact on human signaling
pathways from two perspectives. On a global scale, we found a core set of signaling pathways with enriched tissue-specific
microRNA targets across diseases. The function of these pathways reflects the affinity of microRNAs to regulate cellular
processes associated with apoptosis, proliferation or development. Comparing cancer and non-cancer related microRNAs,
we found no significant differences between both groups. To unveil the interaction and regulation of microRNAs on
signaling pathways locally, we analyzed the cellular location and process type of disease-associated microRNA targets and
proteins. While disease-associated proteins are highly enriched in extracellular components of the pathway, microRNA
targets are preferentially located in the nucleus. Moreover, targets of disease-associated microRNAs preferentially exhibit an
inhibitory effect within the pathways in contrast to disease proteins. Our analysis provides systematic insights into the
interaction of disease-associated microRNAs and signaling pathways and uncovers differences in cellular locations and
process types of microRNA targets and disease-associated proteins.
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Introduction
MicroRNAs are endogenous, non-protein coding, approximate-
ly 22-nucleotide RNA molecules that have recently emerged as
post-transcriptional regulators, known to influence diverse cellular
processes ranging from stem cell differentiation to apoptosis [1].
They mostly target the 39 untranslated region of a target mRNA,
thereby destabilizing the transcript and inhibiting its translation
[2,3]. While there is evidence [4–6] that microRNA expression
and maturation is induced by signaling pathways, microRNAs also
emerge as regulators of signaling proteins. In zebrafish, miR-9 has
been shown to regulate several components of the FGF signaling
pathway, and thus controls neurogenesis in the midbrain-
hindbrain domain during late embryonic development [7]. In
another recent example in fruit fly [8], miR-8 has been identified
to target both a transmembrane protein and a transcription factor
of the WNT signaling pathway. Ricarte-Filho et al. [9] showed
that the RET-pathway is mediated by let-7 which inhibits the
activation of the RET/PTC-RAS-BRAF-ERK cascade exempli-
fying the direct influence of a single microRNA on a submodule of
a signaling pathway. Given the generally large number of
microRNA targets [10] it is natural to assume that many
microRNAs regulate not only a single important pathway protein,
but rather coordinate protein levels on a pathway-wide scale.
Altered microRNA levels might then result in inaccurate target
protein levels, consequently fallacious signal transduction, and
potentially a disease phenotype.
From this perspective, it is intriguing to observe that medical
sciences increasingly focus on the impact of microRNA-mediated
regulatory control on diseases, especially in cancer: microRNAs
are intensively used as diagnostic and prognostic disease markers
[11], and even appear in first clinical trials [12]. Given the linkages
between signaling pathways and microRNA regulation on the one
hand, and microRNAs and disease phenotypes on the other, we
aim to unveil the connection between phenotypes and pathways
induced by microRNA mediated regulatory control.
In this work, we analyzed the tissue-specific regulatory patterns
of disease-associated microRNAs in signaling pathways on
different scales. Globally, we investigated the enrichment of
disease-associated microRNAs on different pathways, and more
locally, on the cellular location and process type of target proteins.
We used manually annotated data from hundreds of patient
studies to estimate the impact of disease-associated microRNAs on
signaling pathways. We identified a core set of pathways,
homogeneously enriched throughout nearly all diseases. Most of
these pathways have been associated with cell growth, prolifera-
tion, and apoptosis. However, deregulation of signaling pathways
can be induced by diverse factors. Point mutation of central
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information flow as well as any change in the expression pattern of
cis or trans regulators. We thus compared the cellular localization
and process type of signaling proteins that are microRNA targets
with proteins that have been identified as disease-associated. In the
following, we show that in contrast to disease proteins, microRNA
targets are significantly enriched as inhibitors within the nucleus.
Results
We captured the different entities of our investigation in a
multipartite graph. The graph consists of five sets of nodes
representing the entities microRNAs, proteins, tissue, diseases, and
pathways and links between but not within the set of nodes. Links are
given by a prediction tool and four databases. MicroRNAs (as
provided by the mirBase database [14]) are linked to diseases and
corresponding tissue via the PhenomiR database [15], a manually
curated database containing disease-associated microRNAs in
human disorders. MicroRNA target transcripts are determined by
TargetScanS [10] a prediction tool that shows a high performance on
different microRNA target data sets [16]. In addition, we used the
tissue atlas provided by Su et al. [17] to filter potential microRNA
targets for a specific disease and a given tissue. We unified the set of
mRNA transcripts and corresponding proteins to a set of nodes
denoted simply as proteins. This set is linked to signaling pathways via
the National Cancer Institute Pathway Interaction Database (NCI
PID) [18], containing 79 human pathways together with its
constituting components. Finally, disease proteins are identified by
their KEGG DISEASE annotation [19] (see Methods for a detailed
description of the materials used). Figure 1 summarizes the entities
and connections used. Notably, similar results were obtained with
other microRNA prediction tools and a different set of disease genes,
as provided by OMIM [20] (for a detailed discussion see Robustness
analysis in File S1).
MicroRNAs induce a core set of signaling pathways
across diseases and tissues
We first analyzed the connection between diseases and signaling
pathways, mediated by disease-associated microRNAs. In order to
project the properties of the multipartite graph onto a disease-
pathway correlation, we calculated the enrichment of disease-
associated microRNA targets in a particular pathway. We used the
tissue annotation in PhenomiR to filter for expressed microRNA
targets, as given by the tissue atlas of Su et al. [17]. For a particular
disease and a specific pathway, we computed the log odds ratio
(LOD score) by dividing the relative number of associated
microRNA targets in this pathway and tissue with the expected
number, based on the relative number of associated microRNA
targets in all signaling pathways given a specific tissue. Disease-
pathway interactions with no targets (white fields in the heatmap
Figure 2A) were excluded from further analyses (see Methods for a
detailed description). We obtained a matrix of LOD scores, where
each entry indicates the enrichment or depletion of tissue-specific
targets of disease-associated microRNAs in the respective signaling
pathway. We ordered this matrix according to a hierarchical
clustering along the disease axis and pathway axis, respectively.
Two features of the resulting heatmap are remarkable: First,
dividing the hierarchical clustering of the signaling pathways into 3
major sub-clusters, we found one cluster (cluster 2; mean
LOD=0.55, variance=0.008) showing a high enrichment
throughout all diseases (see Figure 2A). We define this cluster as
the core set of signaling pathways highly enriched with disease-
associated microRNA targets. The remaining clusters show a high
variance (cluster 3; mean LOD=0.21, variance=0.02) and a
common depletion of microRNA targets (cluster 1; mean
LOD=20.36, variance=0.07). Second, the 63 diseases split into
two clusters with high and low microRNA-pathway associations.
Within the larger of the two clusters, the enrichment of microRNA
targets is extremely homogenous. Moreover we performed a multi-
Figure 1. Illustration of the interactions between diseases, tissue, annotated disease-associated microRNAs, proteins, and human
signaling pathways. The multipartite graphs consists of five sets of nodes and links between them, established by different data resources: 165
microRNAs from the PhenomiR database with annotated deregulation in 63 diseases, 4907 target transcripts, predicted by TargetScanS and filtered
by the tissue atlas, 79 signaling pathways with constitutive proteins as given by the NCI PID database, and finally the subset of disease proteins as
provided by the KEGG DISEASE database.
doi:10.1371/journal.pone.0011154.g001
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bootstrap replication of 20%) [21] to test whether clusters 1–3 are
robust against variation in the data. We can reject the hypothesis
that the clusters do not exist with a significance level av0.05
indicating that the clusters 1–3 may stably be observed by
increasing the number of observations.
All signaling pathways located in the core set are given in
Table 1. The functions of these pathways reflect the affinity of
Figure 2. Impact of disease-associated microRNAs on signaling pathways. Enrichment for a particular disease and pathway was calculated
by a LOD score. A positive score indicates an enrichment of microRNA targets for a disease-pathway interaction. Negative scores indicate depletion.
A: Heatmap of microRNA target enrichment for a particular disease and pathway. Pathways and diseases are ordered by hierarchical clustering using
Manhattan distance and ward clustering. B: Boxplot of disease-pathway associations ordered according to hierarchical clustering along the pathways.
Red fields indicate an enrichments and blue a depletion. White fields indicate that no microRNA targets were found for this disease-pathway
association.
doi:10.1371/journal.pone.0011154.g002
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sis, proliferation or development, as we will outline with three
examples. (i) The PDGFa pathway, for example, promotes cell
migration, proliferation, and survival [22–25]. PDGF expression
has been demonstrated in a number of different solid tumors, from
glioblastomas to prostate carcinomas. Its biological function varies
from autocrine stimulation of cell growth to subtler paracrine
interactions involving adjacent stroma or vasculature [26]. (ii) It
was recently reported that let-7 has an influence on the RET-
pathway by effecting the cell growth and differentiation of
papillary thyroid cancer [9]. Ricarte-Filho et al. [9] concluded
that let-7 inhibited the activation of the RET/PTC-RAS-BRAF-
ERK cascade exemplifying the direct influence of a single
microRNA on a submodule of a signaling pathway. (iii) The
Reelin pathway has been directly correlated with tumor
aggressiveness [27–29]. Evangelisti et al. [30] linked this pathway
for the first time to cancer by showing the inhibition of Reelin by
miR-124a.
The pathways with the highest negative enrichments, as
depleted by disease-associated microRNA targets, are the IL-23
mediated pathway (playing a pivotal role in autoimmunity [31])
and BRAD1, which is associated with cell survival and cell death
[32]. Although we found a core set of pathways across diseases,
differences between disorders can arise due to different expression
levels of the respective microRNAs. The PDGFa pathway for
example shows high enrichments across diseases independent of
the microRNA prediction tool (see Table S1). We found miR-144
to be highly enriched in the PDGFa pathway. Analyzing the
expression profile, we found miR-144 down-regulated in cancer,
but up-regulated in Parkinson disease and idiopathic Myelofibro-
sis. Predicted targets of miR-144 are SRF, a transcription factor
activated by PDGFa, and FOS that is thought to have an
important role in signal transduction, cell proliferation and
differentiation [33–35]. This finding shows that although different
diseases are associated with the same signaling pathway,
differences in the effects of the stimulated pathways can be
induced by complementary expression profiles of microRNAs.
As the PhenomiR data set is dominated by cancer-related
diseases (60%), we divided the set of diseases into a subset of
cancer and non-cancer related microRNAs to study differences
between both groups. We found 14 out of 16 pathways of the
global core set also in the cancer-specific core set (see Table S2).
The core set for the non-cancer related pathways contains 12
pathways that were also found by the global data set, but we also
identify also two non-cancer specific pathway enrichments (see
Table S3) such as the KIT pathway and the NFkB pathway, that is
involved in the expression of genes associated with development,
cell death, and immune response [36–39].
Robustness analysis of the core set of signaling pathways
In order to ensure that our results are not artifacts of the chosen
prediction tool, we analyzed the data with four other prediction tools:
PicTar [40], Miranda [41], TargetSpy [42], and RNA22 [43].
Different features like conservation of the seed region or binding
energies are taken into account to predict microRNA-transcript
interactions in each tool. Based on these differences the overlap
between the target sets from different tools is generally rather low
[44]. Wedefine for eachtool the core set ofsignaling pathways, which
are highly enriched by microRNA targets and compare these list with
our core set listed in Table 1. The result shows that the signaling
pathways in our core set are mostly consistent with different
prediction tools (see Table S1). We found 8 out of 16 pathways
within the core set of at least 3 different prediction tools.
In order to test the significance of these pathways, we performed a
randomization approach, by comparing the median LOD score of
these pathways with the median scores obtained by two random
samplings. We first sampled 10.000 times pathway proteins keeping
the pathway size constant, second, we generated 10.000 times a
random microRNA predictor by sampling for each microRNA the
corresponding targets. Finally, we calculated a z-score to estimate the
significance of each pathway within the core set. We obtained high z-
scores for the pathways within the core set independent of the
sampling approach (see Table 1). The mean z-score for all pathways
is 12.51 (Z-scoreTargets)a n d7 . 6 5( Z - s c o r e Pathways), respectively.
The enrichment of microRNA targets is summarized in the
boxplot in Figure 2B, where the distribution of LOD scores for
each pathway is shown. The median LOD scores and their
variance for the set of signaling pathways are significantly
negatively correlated (Pearson correlation coefficient
CP ={0.37, P~7:10{3, see Figure S1). In contrast to depleted
pathways, highly enriched pathways are homogeneously targeted
by microRNAs across diseases. This indicates that disease-
associated microRNAs in human disorders target a core set of
signaling pathways irrespective of the specific disease and tissue.
We ensure that the LOD scores are not trivially biased by the
pathway size (CP =20.032, P~0:83) and show the respective plot
in Figure S2. We noticed that the pathway enrichment is
significantly negatively correlated with the number of microRNAs
with targets in this pathway (CP =20.31, P~0:0010), with up to
159 targeting microRNAs in the SMAD2 pathway.
Interaction of disease-associated proteins and microRNA
targets
Much effort has been invested in understanding the mechanisms
underlying the complex network of factors contributing to human
diseases. Databases like OMIM [20], KEGG DISEASE [19], or
Table 1. Core set of signaling pathways with highly enriched
microRNA targets.
Pathway Median LOD microRNA Z-scoreTargets Z-scorePathways
Rhodopsin 0.76 miR-154 8.69 6.58
Botulinum 0.61 miR-29b 8.58 8.10
TGFBR 0.61 miR-216a 12.20 7.10
BMP 0.60 miR-224 9.37 7.93
IGF1 0.59 miR-375 9.39 8.12
VEGFR3 0.57 miR-422a 8.29 7.89
EphrinB/EPHB 0.57 miR-422a 11.44 8.06
PDGFa 0.56 miR-383 7.20 7.59
MET 0.55 miR-422a 10.96 7.61
EphrinA/EPHA 0.53 miR-136 8.31 8.15
RET 0.52 miR-422a 9.04 7.24
VEGFR1 0.51 miR-422a 11.72 7.82
REELIN 0.51 miR-197 7.76 6.86
TRKR 0.49 miR-335 12.94 7.88
mTOR4 0.47 miR-375 7.23 7.44
EPO 0.43 miR-134 6.75 8.00
The Median LOD score is calculated over all diseases for a particular pathway.
MicroRNA is the most enriched single microRNA within the corresponding
pathway. Z-scoreTargets was calculated by comparing the median LOD score
with the obtained score by a random sampling of microRNA targets. Z-
scorePathway was calculated by comparing the median LOD score with the
obtained score by a random sampling of pathway proteins.
doi:10.1371/journal.pone.0011154.t001
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human disorders. In order to focus on already confirmed gene-
disease interactions, we used the KEGG DISEASE database to
study similarities and differences to microRNA targets in signaling
pathways. In the following, we analyzed 23 diseases that are both
annotated in KEGG DISEASE and PhenomiR (see Methods). In
this subset, we analyzed 365 KEGG DISEASE proteins located in
the NCI PID signaling pathways and identified 123 (33.7%)
proteins as microRNA targets. The current estimation for the
amount of microRNA targets in the human genome lies between
30–35% [10,46]. This implies that there is no higher rate of
microRNA targets in the set of disease proteins than expected. In
order to study the interplay of disease proteins and microRNA
targets, we compared their mapping to NCI PID pathways (see
Figure 1). We found that typically, disease-affected proteins are
widely distributed over pathways for a particular disease. Focusing
on pathways showing a high fraction of disease-associated proteins,
we found no correlation of microRNA target enrichment and the
fraction of disease-affected signaling proteins (see Figure S3).
These findings imply that disease-affected proteins and disease-
associated microRNA targets do not prefer a common set of
signaling pathways. To elucidate those differences, we changed the
scale of our investigation and compare the localization and process
type of disease-associated microRNA targets and disease proteins.
MicroRNA targets are preferentially located in the
nucleus in contrast to disease proteins
To question whether microRNA targets and KEGG DISEASE
proteins differ with respect to their cellular location and process
type annotation, we divided the set of signaling proteins according
to their NCI PID annotation into four groups: extracellular region,
cell membrane, intracellular region, and nucleus. We then
estimated the fraction of microRNA targets as well as disease
proteins for each group and calculated the LOD enrichment
scores (see Methods for a detailed description). Surprisingly, we
found opposing patterns of cellular localization for disease-
associated proteins and microRNA targets (see Figure 3A).
Deregulated microRNAs preferentially target nuclear proteins
(LOD=0.57, p~0:020), while disease-associated proteins in the
nucleus are underrepresented (LOD=20.41, p~0:032). There-
fore, microRNA targets are almost twice more frequently located
in the nucleus as compared to disease proteins. Furthermore,
proteins located in extracellular region are only weakly controlled
(LOD=20.81, p~4:9:10{3) by microRNAs. Disease associated
proteins showing again a complementary result compared to
microRNA targets (LOD=0.44, p~0:068), being more than
twice more frequently located in the extracellular region. Proteins
located in the cell membrane or intracellular region show no
significant differences and enrichments for microRNAs or disease-
associations. Comparing these results with the subset of cancer-
related microRNAs we obtained the similar finding of a preferred
target location in the nucleus. This result shows that preferred
location is not based on a disease-specific set but a common
pattern, valid for cancer as well as non-cancer related microRNAs
(see Figure S4). We repeated the location analysis with different
prediction tools and obtained similar results for microRNA targets
(see Figure S5). Analyzing microRNA targets located in the
nucleus by Gene Ontology, we found 50% of those genes involved
in transcriptional regulation. In addition, we used the OMIM
Figure 3. Analysis of cellular location and process type distribution for microRNA targets and disease proteins. A: Signaling proteins
are divided into four different cellular location groups (extracellular region, cell membrane, intracellular region, and nucleus) based on their NCI PID
annotation. We calculated the enrichment of microRNA targets and disease proteins by a LOD score. We found an opposing patterns of cellular
localization for disease-associated proteins and microRNA targets. B: Process type information obtained by the NCI PID database was used to divide
signaling proteins into three different groups, activators, inhibitors, and ambivalent proteins (annotated as both activators and inhibitors). The result
indicates again complementary patterns for microRNA targets and human disease proteins. * indicates significant enrichment obtained by Fisher’s
exact test (P~0:05).
doi:10.1371/journal.pone.0011154.g003
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opposite pattern of cellular localization for OMIM and microRNA
targets (see Figure S6).
In contrast to disease proteins, microRNA targets
frequently exhibit an inhibitory effect
We sorted the set of signaling proteins into three different
groups according to their process type annotation: activating
proteins, inhibiting proteins and proteins that can act as either
activators or inhibitors, further on denoted as ambivalent. We then
counted the number of microRNA targets as well as disease
proteins for each group in our signaling pathways and calculated
the LOD score. The result shows again a complementary pattern:
As shown in Figure 3B, targets of disease-associated microRNAs
are preferentially inhibitors (LOD=1.62, p~1:2:10{4), whereas
only 6 disease-associated proteins (LOD=22.08, p~1:5:10{5)
show a inhibitory effect. MicroRNA targets are enriched almost 14
times more in inhibiting proteins compared to disease proteins
showing a complementary focus. Ambivalent proteins show a
strong under-representation for microRNA targets (LOD=20.96,
p~7:3:10{5), whereas disease-affected proteins are significantly
enriched (LOD=1.26, p~3:6:10{9). For activators, we found a
significant under-representation for both disease proteins
(LOD=20.75, p~1:0:10{4), and microRNA targets
(LOD=20.60, p~2:7:10{3), respectively. Again, we found the
same result for cancer and non-cancer related microRNA targets
indicating a common pattern. Notably, the enrichment of process
types of disease proteins remains for the OMIM data set (see
Figure S7).
Discussion
In order to study the role of disease-associated microRNAs in
pathways, we applied a thorough statistical analysis to a
multipartite graph consisting of microRNAs, proteins, diseases,
tissue and signaling pathways. We investigated enrichment of
disease-associated microRNAs globally on different pathways by
considering of tissue-specific transcript expression, and more
locally, on the cellular location and process type of target proteins.
We found that the amount of regulatory control mediated by
disease-associated microRNAs differs from pathway to pathway.
In [47], the authors showed that the targets of a specific
microRNA cluster are significantly enriched in multiple pathways.
For the majority of diseases, a homogeneous enrichment profile of
microRNA targets throughout all pathways emerged. From our
analysis of the constituting multipartite graph, we found that
pathways are heterogeneously targeted by microRNAs. However,
the core set of pathways under strong microRNA control appear
to be homogeneously enriched throughout the majority of
diseases, since many diseases are linked to a large number of
microRNAs. So far, almost two third of the currently known
microRNAs are linked via large-scale expression analysis to a
phenotype. It is obvious that beside the phenotype responsible
microRNAs, many microRNAs are detected as deregulated in
human diseases but are not functionally linked to the phenotype.
What could be the biological function of a core set of globally
enriched pathways? We showed that these pathways are targets of
numerous deregulated microRNAs. One possible hypothesis is
that these pathways could serve as disease sensors, transferring the
information of erroneous cellular functions via deregulated
microRNAs to important output proteins, like cell cycle check-
points. From this perspective, it is intriguing that most top
enriched pathways are associated with apoptotic, proliferation or
developmental processes [48]. Entries in the PhenomiR database
obtained by patient studies are more than 60% cancer-related
diseases. Alterations in the expression or function of genes
controlling cell growth and differentiation are considered to be
the major cause of cancer. Notably, degenerative disorders like
Alzheimer or Parkinson disease show a similar pathway profile
compared to cancer-related phenotypes, although often with
different direction of microRNA expression.
Presumably, the impact on signaling pathways for disease-
associated proteins and microRNA targets differs. However, there
might be an interaction between the disease-associated micro-
RNAs and proteins to mediate deregulation of signaling pathways.
It would be interesting to evaluate whether a given disease emerges
due to protein deregulation caused by mutations with a successive
deregulation of microRNAs, or due to deregulated microRNA
levels, leading to pathogenic protein levels in turn. For a subset of
microRNAs, located in the intron of a host gene, an examination
of a common phenotypic effects is possible. Recently, we showed
that intronic microRNAs support the regulatory effect of their host
genes [49]. Here, we find one disease-associated microRNA-target
pair with a common phenotype: both the host gene PTK2 and its
intronic microRNA miR-151 are annotated with lung cancer in
KEGG DISEASE and PhenomiR, respectively. In this case, the
impact on the associated signaling pathways via correlated mir-
151 and PTK2 deregulation is probably controlled by a single
promoter. To unveil interactions between microRNAs and
pathway proteins on a systems level, a much more precise
knowledge of microRNA transcriptional regulation is needed.
We analyzed the subcellular location and process type behavior
of disease-associated proteins and microRNA targets. Our result
on the preferred cellular locations of microRNA targets shows an
enrichment of proteins in the nucleus. This finding is in line with a
study by Cui et al. [50], who obtained a similar result for the
localization of microRNA targets on a much smaller set of
signaling networks and microRNAs in mammalian hippocampal
CA1 neurons. In addition, we found that disease-associated
proteins often constitute the initial players of signaling networks
and thus show an opposite pattern to microRNA targets. The
deregulation of a single proteins at the cell surface receptor can
have a severe impact on the whole signaling information flow
stimulated by the receptor. For example, for growth factor
receptors, the activation under normal conditions promotes
cellular survival, whereas over-expression promotes tumor cell
growth [51]. Therefore, cell surface receptors are well suited as
drug targets, as diminishing the signal through these receptors has
the potential to normalize cellular behavior. The deregulation of a
single protein in the intracellular region or the nucleus might
influence only a subpart of the signaling network.
A large fraction (50%) of microRNA targets located in the
nucleus are involved in transcriptional regulation. It was shown
that transcription factors like MYC, JUN, or FOS, have a short
mRNA lifetime based on their RNA stability [52,53]. Within these
studies the importance of the 39 untranslated region for the mRNA
stability was mentioned. Thus, microRNAs presumably tune RNA
stability in a tissue or stage dependent manner. Deregulated
microRNAs changing the stability of transcription factors of a
signaling pathway may then lead to malfunction of different
cellular processes [54]. Motivated by the affinity of microRNAs to
regulate with associated pathways apoptosis, proliferation or
development [1], we suppose that the regulation of stability
extends to proteins with short half-lives that are required only for
limited time in, e.g., cell cycle, growth, or differentiation.
In a recent study, Legewie et al. [55] introduced a set of signal
inhibitors with a short mRNA and protein lifetime that are
transcriptionally induced upon stimulation. These rapid feedback
miRNAs in Signaling Pathways
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cascades, allow for swift feedback regulation and establish short
latency phases after signaling induction. As we found an
enrichment of inhibitory proteins targeted by microRNAs, the
question arises, if RFI proteins are potential microRNA targets.
Using the TargetScanS prediction tool we were able to confirm 18
out of 19 (95%) RFIs as microRNA targets (P~0:023). We thus
assume that the short mRNA lifetime of RFIs can be attributed to
the degradation activity promoted by microRNA binding.
Inhibiting proteins are preferentially located in the nucleus (see
Table S4), whereas activating or ambivalent proteins are randomly
distributed in the cellular regions. Interestingly, disease proteins
showed a frequent association with ambivalent process type. We
assume that for ambivalent proteins, deregulation of the
expression levels imparts a more severe effect on signaling
cascades as compared to activators or inhibitors alone.
The usage of hypergraphs for a proper representation of
interconnected entities in systems biology has been acknowledged
recently [56]. Here, we applied a thorough statistical analysis not
only to bipartite but to a multipartite graph consisting of
microRNAs, proteins, diseases, and signaling pathways in a
tissue-specific manner and uncovered the impact of disease-
associated microRNAs on human signaling pathways.
Materials and Methods
In this section, we give a detailed overview about the resources
and methods, which were used to interconnect the different
entities shown in Figure 1.
Human signaling pathway data
Human signaling pathway data was obtained from the
National Cancer Institute Pathway Interaction Database (NCI
PID) [18], which is a manually curated collection of biomolecular
interactions and key cellular processes assembled into signaling
pathways. NCI PID holds 128 pathways including 47 sub-
networks. We combined all subnetworks with their parent
networks to the set of signaling pathways. In addition, we kept
all pathways that have more than one predicted microRNA
target gene, leading to a final data set of 79 human signaling
pathways containing 1573 unique human proteins. The database
also provides information on subcellular location terms from the
Gene Ontology Consortium. We used this information to divide
all subcellular locations into four different groups: extracellular
region, cell membrane, intracellular region and nucleus. Finally,
location information for 1083 proteins containing 135 extracel-
lular region, 344 cell membrane, 373 intracellular region and 231
proteins located in the nucleus were obtained. In addition, we
extracted process type information for each biological process,
which can be input, output, positive or negative regulator. In
total, there are 1120 interactions of which 765 are activating, 74
inhibiting and 281 proteins acting as activators as well as
inhibitors.
Disease-associated microRNAs
Human disease-associated microRNAs were obtained from the
PhenomiR database [15]. PhenomiR is a manually curated
collection of microRNA-disease associations, containing a total
of 11 029 microRNA expression-phenotype relations collected
from 542 different experiments. We used patient study data only
and obtained 486 disease-associated microRNAs in 83 different
diseases including up to 5 subtypes per disorder. For each disease,
we take only those microRNA into account, that have at least one
target in the specific tissue annotated by PhenomiR and obtained
finally 165 different microRNAs in 63 diseases-tissue combina-
tions.
MicroRNA target prediction
Hausser et al. [16] analyzed different features of microRNA
targets and showed within their work that TargetScanS has a good
performance on different data sets. We used TargetScanS as the
main prediction tool but to handle the issue of the unknown
reliability of microRNA prediction tools we used several other
prediction tools like PicTar, intersection of PicTar and TargetS-
canS, Miranda, RNA22, and TargetSpy to confirm our results.
We used for each method default parameter settings.
MicroRNA targets filtered by tissue expression
As microRNA expression is tissue-specific annotated in
PhenomiR, we used the tissue atlas provided by Su et al. [17] to
filter potential microRNA targets in a specific tissue. The data was
downloaded from the NCBI Gene Expression Omnibus (GEO),
and the processed data was used. We mapped the predicted
microRNA target transcripts on the tissue atlas and considered a
transcript as expressed in a specific tissue, if either one replicate
has a present call or both show at least a marginal call, similar to
the work of McClintick et al. [57].
Human disease data
Human disease proteins were taken from the KEGG DISEASE
database [19]. It associates 5 neurodegenerative disorders, 5
infectious and metabolic disorders and 13 different cancer
diseases. Finally, we obtained 909 proteins from 23 different
diseases, which are also found in the PhenomiR database. For
results obtained by the NCBI OMIM database see Figure S6 and
Figure S7.
Pathway profile
Pathway profiles were calculated for all diseases annotated in
PhenomiR passing the tissue filter. For each disease-pathway
interaction we estimated the enrichment of microRNA targets of
disease i in pathway j defined by a log odds ratio (LOD score):
LODi,j~log2
Ti,j
Pj
 Pn
k~1 Ti,k Pn
k~1 Pk
  
where Ti,j is the number of microRNA targets for all disease-
associated microRNAs in disease i and pathway j; Pj is the
number of proteins in pathway j;
Pn
k~1 Ti,k is the number of
microRNA targets for all disease-associated microRNAs in disease
i over all pathways;
Pn
k~1 Pk: is the number of proteins over all
pathways. We use these LOD scores to build up a heatmap using
Manhattan distance function and ward clustering. A positive value
indicates an enrichments and a negative a depletion. Whenever we
identified no target for a particular disease-pathway interaction
Ti,j~0 and therefore the resulting LOD scorei,j is {?.A s
commonly done, we excluded all cases with Ti,j~0 for calculating
the mean and quantiles for each pathway. In addition, these cases
were also excluded from the clustering taking the reduced
dimensions into account.
Cellular location analysis
We used the subcellular location annotation of the NPI PID
database to estimate the microRNA target enrichment. The
enrichment was calculated by the logarithm of base 2 of the odds
ratio (LOD score) and its significants was obtained by Fisher’s
exact test.
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In addition to the subcellular location, the NPI database
provides information about specific process types of proteins in
signaling processes. We used this information to analyze the
interaction between inhibiting as well as activating proteins in
signaling processes. Within this analysis we calculated the
enrichment of microRNA targets as well as KEGG DISEASE
proteins for different process types. The enrichment was calculated
by the logarithm of base 2 of the odds ratio (LOD score) and its
significants was obtained by Fisher’s exact test.
Supporting Information
File S1 Robustness analysis.
Found at: doi:10.1371/journal.pone.0011154.s001 (13.55 MB
PDF)
Figure S1 Anticorrelation of median LOD score against
variance for signaling pathways. We obtained a significant
negative correlation (Pearson correlation coefficient Cp=20.37,
P=0.007). The result implies that deregulated microRNAs in
human diseases target the same set of signaling pathways
irrespective of the specific disorder. The results of the linear
regressions is shown by the black line.
Found at: doi:10.1371/journal.pone.0011154.s002 (0.12 MB TIF)
Figure S2 Pathway size against pathways ordered by median
LOD score. We found no correlation (Cp=20.032, P=0.83)
between pathway size against pathways ordered by median LOD
score. The results of the linear regressions is shown by the black
line.
Found at: doi:10.1371/journal.pone.0011154.s003 (0.15 MB TIF)
Figure S3 Correlation between KEGG DISEASE proteins and
microRNAs in signaling pathways, using 24 diseases both
annotated in PhenomiR and KEGG DISEASE. Median LOD
score of signaling pathways against the fraction of disease-
associated pathway proteins (Cp=0.14, P=0.21). We consider
all pathways showing a fraction of disease-associated proteins
$0.2. We observe no significant correlation between increasing
LOD scores and the fraction of disease proteins even if we exclude
the outlier (marked in red) (Cp=0.18, P=0.127). The results of
the linear regressions is shown by the black line.
Found at: doi:10.1371/journal.pone.0011154.s004 (0.15 MB TIF)
Figure S4 Comparison between different disease sets. Observed
LOD scores for cellular location of all disease-associated micro-
RNA targets and two subsets of diseases (Cancer, Non Cancer)
using TargetScanS. For cancer and non cancer, we observed
similar scores compared to scores obtained by using all diseases
showing that the location pattern is rather a common result and
not depended on the subsets of cancer and non-cancer related
microRNAs.
Found at: doi:10.1371/journal.pone.0011154.s005 (0.14 MB TIF)
Figure S5 Comparison between different microRNA prediction
tools. Observed LOD scores for cellular location of several
microRNA prediction methods (Intersection of PicTar and
TargetScanS, TargetScanS, PicTar, Miranda, TargetSpy, and
RNA22) and KEGG DISEASE proteins. Different features like
conservation of the seed region (e.g., TargetScanS) as well as
binding energies (e.g., Miranda) are taken into account to predict
microRNA-transcript interactions. Based on differences in these
prediction methods the overlap between the targets from different
tools is low (Sethupathy, 2006). In this work, it was also shown
that Miranda has similar high sensitivity compared to the top
method like TargetScanS, but exhibit a substantial increase in the
number of total predictions. This could be one explanation why
Miranda shows a different result for microRNA targets in
extracellular and intracellular regions compared to the remaining
prediction tools, which show very similar results. The findings
indicate robustness of our results, independent on the prediction
tools. In addition, this findings support our result of complemen-
tary behavior of KEGG DISEASE proteins and microRNA
targets.
Found at: doi:10.1371/journal.pone.0011154.s006 (0.19 MB TIF)
Figure S6 Comparison between different disease gene sets.
Observed LOD scores for cellular location of microRNA
targets and two sets of disease-associated genes (KEGG
DISEASE and OMIM). For OMIM, we observed similar
scores compared to KEGG DISEASE proteins that confirms
our finding and shows robustness of our results. In addition,
this finding supports our result of complementary behavior of
disease-associated genes (KEGG DISEASE and OMIM) and
microRNA targets.
Found at: doi:10.1371/journal.pone.0011154.s007 (0.15 MB TIF)
Figure S7 Comparison between different disease gene sets.
Observed LOD scores for process type behavior of microRNA
targets and two sets of disease-associated genes (KEGG DISEASE
and OMIM). For OMIM, we observed similar scores compared to
KEGG DISEASE proteins that confirms our finding. In addition,
this finding supports our result of complementary behavior of
disease-associated genes (KEGG DISEASE and OMIM) and
microRNA targets.
Found at: doi:10.1371/journal.pone.0011154.s008 (0.15 MB TIF)
Table S1 Core set of signaling pathways. Prediction tools show
the fraction of different tools having the corresponding pathway
within the top cluster.
Found at: doi:10.1371/journal.pone.0011154.s009 (0.02 MB
XLS)
Table S2 Core set of signaling pathways obtained by the cancer
related microRNAs. Prediction tools show the fraction of different
tools having the corresponding pathway within the top cluster.
Found at: doi:10.1371/journal.pone.0011154.s010 (0.02 MB
XLS)
Table S3 Core set of signaling pathways obtained by the non-
cancer related microRNAs. Prediction tool shows the fraction of
different tools having the corresponding pathway within the top
cluster.
Found at: doi:10.1371/journal.pone.0011154.s011 (0.02 MB
XLS)
Table S4 Correlation between cellular location and process
type. Number of signaling proteins within the four different
cellular locations and three different process types.
Found at: doi:10.1371/journal.pone.0011154.s012 (0.03 MB
XLS)
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